Prof. Wolfgang Janni — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Prof. Wolfgang Janni appears in 6 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials6

Recruiting shown3

Roles1

SourceClinicalTrials.gov

Clinical trials

6 shown

A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular RelapseNCT06643585 · lead sponsor · 2025-04-22

Standard Surveillance vs. Intensive Surveillance in Early Breast CancerNCT05658172 · lead sponsor · 2022-12-07

Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect ManagementNCT05362760 · lead sponsor · 2022-04-27

Detect V / CHEVENDO (Chemo vs. Endo)NCT02344472 · lead sponsor · 2015-09-01

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).NCT02035813 · lead sponsor · 2014-01-01

DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCsNCT01619111 · lead sponsor · 2012-02-01

Sponsor roles

lead sponsor6

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.